Mechanistic target of rapamycin (mTOR)
The Mechanistic target of rapamycin kinase (Mtor) is a central serine/threonine kinase that integrates growth factor, nutrient, energy, and stress signals to regulate cell growth, metabolism, protein synthesis, autophagy, and survival.
The Mechanistic target of rapamycin kinase (Mtor) is a central serine/threonine kinase that integrates growth factor, nutrient, energy, and stress signals to regulate cell growth, metabolism, protein synthesis, autophagy, and survival. It is a core component of the PI3K/AKT/mTOR pathway, and its activity is tightly linked to cellular adaptation in both normal physiology and disease. Because of this broad regulatory role, Mtor is a major biomedical target in oncology, inflammatory disease, metabolic disorders, neurodegeneration, and tissue repair.
Pharmacologically, Mtor is best known as the target of sirolimus and everolimus, which suppress Mtor signaling and are used in several clinical settings. In recent research, Mtor has also been studied in connection with AMPK/mTOR, Phosphatidylinositol 3-kinase (PI3K)/Protein kinase B (PKB), Mtor-TFEB, and related autophagy and lysosomal pathways, reflecting its role as a signaling hub that can either promote anabolic growth or restrain autophagy depending on cellular context.
Where the papers sit
19 papers from the last 6 months study Mechanistic target of rapamycin (mTOR) directly · updated from PubMed 12 Nov 2026
Study type 0 clinical trials · 2 observational · 2 human data · 13 preclinical · 2 unclassified
Themes 4 themes
-
mTOR-Targeted Disease Therapy
mTOR inhibition is being explored across lung and breast cancers, lymphangioleiomyomatosis, and post-transplant malignancy prevention. Sirolimus and everolimus recur alongside approaches intended to improve delivery or overcome resistance. ROS-linked apoptosis and glutamine dependence, including combined mTOR–GLS1 blockade, provide recurring mechanistic targets. The evidence remains disease-specific rather than establishing one treatment strategy.
5 papers · 26.3%
-
AMPK-mTOR and Autophagy
AMPK-mTOR control of autophagy and mitophagy is being pursued as a route to repair metabolic and degenerative tissue injury. Urolithin A improves cardiac remodeling through mitophagy, while macrophage autophagy supports diabetic foot healing. Metformin, butyrate, and pathway-focused interventions extend the work toward neuropathy and amyloid transport, but clinical evidence remains limited. Restoring autophagic flux, rather than simply inhibiting mTOR, is the recurring therapeutic aim.
5 papers · 26.3%
-
Others — mTOR-Linked Disease Signaling
mTOR-linked signaling recurs in inflammation, fibrosis, neuronal injury, and tumor behavior across otherwise distinct diseases. TSC1/miR-331-3p, NFκB, CCR5hi monocytes, and TIGIT/CD155 represent separate regulatory contexts. Autophagy and apoptosis are common endpoints, but the proposed mechanisms and tissues differ substantially. No unified therapeutic direction emerges from this heterogeneous set.
6 papers · 31.6%
-
Others — mTOR Therapeutics Across Diseases
mTOR dysregulation is linked separately to plaque lipophagy, gastric-cancer resistance to PD-1 blockade, and feline hypertrophic cardiomyopathy. The proposed axes include NPC2-mediated lipid handling and ITGA2-mTOR-CTSV signaling. Evidence ranges from multi-omics analysis to in silico inhibitor discovery, with no shared therapeutic regimen. These studies mainly define disease-specific targets rather than a common treatment direction.
3 papers · 15.8%
Papers
The 19 papers from the last 6 months that study Mechanistic target of rapamycin (mTOR) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
mTOR-Targeted Disease Therapy (5)
- Clinical Characteristics and Outcomes of Patients with Lymphangioleiomyomatosis. Lung · 5 Oct 2026 PMID 42832099
- A derivative of cytisine N-isoflavone from Sophora alopecuroides L., suppresses non-small cell lung cancer by targeting mTOR. European journal of pharmacology · 17 Jul 2026 PMID 42468678
- Everolimus and de novo malignancies after liver transplantation: A nationwide emulated trial using real-world data. JHEP reports : innovation in hepatology · 7 Jul 2026 PMID 42413767
- Synergistic dual targeting of mTOR and GLS1 overcomes glutamine-driven resistance in triple-negative breast cancer. Pharmacological research · 11 Jun 2026 PMID 42276398
- Multi-mechanistic mitochondria-mediated N-methylated YKWYYRGAA-decorated nano-chitosan conjugate carrier for treatment of NRAS-mutant-harbouring lung carcinoma. Carbohydrate polymers · 2 Jun 2026 PMID 42230031
AMPK-mTOR and Autophagy (5)
- Safety and efficacy of metformin for the treatment of pain: protocol for a systematic review. BMJ open · 17 Jul 2026 PMID 42468965
- Urolithin A activates mitophagy via the AMPK-mTOR axis and modulates the gut-ceramide axis to ameliorate cardiac remodeling in HFpEF. Experimental & molecular medicine · 10 Jul 2026 PMID 42432192
- Molecular mechanisms of autophagy disorder in diabetic neuropathy: Focusing on signaling pathways and regulation of lipid metabolism. PloS one · 9 Jul 2026 PMID 42424320
- Asymmetric hydrogel with "spear-shield" properties promotes diabetic foot ulcer healing by modulating macrophage autophagy. Journal of controlled release : official journal of the Controlled Release Society · 6 Jul 2026 PMID 42409241
- Butyrate Regulates the Blood-Brain Barrier Transport and Intraendothelial Accumulation of Alzheimer's Disease Amyloid-Beta Peptides. Molecular pharmaceutics · 21 May 2026 PMID 42166642
Others — mTOR-Linked Disease Signaling (6)
- Metabolic-epigenetic rewiring of CCR5hi monocytes sustains long-term trained immunity against lethal sepsis. Science advances · 21 Aug 2026 PMID 42627899
- Artemisinin liposomes regulates breast cancer metastasis and apoptosis through TIGIT/CD155 signal axis. Apoptosis : an international journal on programmed cell death · 27 Jul 2026 PMID 42507162
- An Integrative RNA Spliceosomic Landscape of Pancreatic Neuroendocrine Tumors Identifies Clinically Relevant Molecular Subgroups. Endocrine pathology · 9 Jul 2026 PMID 42424015
- Exosomes from diabetic perirenal adipose-derived MSCs promote inflammation and fibrosis in diabetic nephropathy via the miR-331-3p/TSC1/mTORC1 Axis. International immunopharmacology · 8 Jul 2026 PMID 42419147
- SMN haploinsufficiency exacerbates high glucose dialysate-induced peritoneal inflammation and fibrosis via mTOR/NFκB signaling pathway. Biochimica et biophysica acta. Molecular cell research · 19 Jun 2026 PMID 42320860
- Platelet-rich plasma-primed bone marrow mesenchymal stem cell-derived exosomes inhibit neuronal apoptosis and autophagy, and promote nerve regeneration via the miR-29a-3p/PTEN/PI3K/Akt/mTOR axis after spinal cord injury. Journal of molecular histology · 21 May 2026 PMID 42165939
Others — mTOR Therapeutics Across Diseases (3)
- A novel mTORC1-NPC2 axis suppresses lipophagy and drives atherosclerotic plaque progression. Biochimica et biophysica acta. Molecular basis of disease · 9 Sept 2026 PMID 42716142
- Streptococcus anginosus-associated kynurenic acid drives PD-1 blockade resistance through an ITGA2-mTOR-CTSV axis in gastric cancer. Journal for immunotherapy of cancer · 6 Aug 2026 PMID 42562425
- In Silico Discovery of mTOR Inhibitors as Potential Therapeutics for Feline Hypertrophic Cardiomyopathy. Journal of molecular modeling · 29 Jun 2026 PMID 42371166
By study type
Observational studies and case reports (2)
- Clinical Characteristics and Outcomes of Patients with Lymphangioleiomyomatosis. Lung · 5 Oct 2026 PMID 42832099
- Everolimus and de novo malignancies after liver transplantation: A nationwide emulated trial using real-world data. JHEP reports : innovation in hepatology · 7 Jul 2026 PMID 42413767
Human data, design not indexed (2)
- Safety and efficacy of metformin for the treatment of pain: protocol for a systematic review. BMJ open · 17 Jul 2026 PMID 42468965
- An Integrative RNA Spliceosomic Landscape of Pancreatic Neuroendocrine Tumors Identifies Clinically Relevant Molecular Subgroups. Endocrine pathology · 9 Jul 2026 PMID 42424015
Preclinical: animal, cell and lab studies (13)
- Metabolic-epigenetic rewiring of CCR5hi monocytes sustains long-term trained immunity against lethal sepsis. Science advances · 21 Aug 2026 PMID 42627899
- Streptococcus anginosus-associated kynurenic acid drives PD-1 blockade resistance through an ITGA2-mTOR-CTSV axis in gastric cancer. Journal for immunotherapy of cancer · 6 Aug 2026 PMID 42562425
- Artemisinin liposomes regulates breast cancer metastasis and apoptosis through TIGIT/CD155 signal axis. Apoptosis : an international journal on programmed cell death · 27 Jul 2026 PMID 42507162
- A derivative of cytisine N-isoflavone from Sophora alopecuroides L., suppresses non-small cell lung cancer by targeting mTOR. European journal of pharmacology · 17 Jul 2026 PMID 42468678
- Molecular mechanisms of autophagy disorder in diabetic neuropathy: Focusing on signaling pathways and regulation of lipid metabolism. PloS one · 9 Jul 2026 PMID 42424320
- Exosomes from diabetic perirenal adipose-derived MSCs promote inflammation and fibrosis in diabetic nephropathy via the miR-331-3p/TSC1/mTORC1 Axis. International immunopharmacology · 8 Jul 2026 PMID 42419147
- Asymmetric hydrogel with "spear-shield" properties promotes diabetic foot ulcer healing by modulating macrophage autophagy. Journal of controlled release : official journal of the Controlled Release Society · 6 Jul 2026 PMID 42409241
- In Silico Discovery of mTOR Inhibitors as Potential Therapeutics for Feline Hypertrophic Cardiomyopathy. Journal of molecular modeling · 29 Jun 2026 PMID 42371166
- SMN haploinsufficiency exacerbates high glucose dialysate-induced peritoneal inflammation and fibrosis via mTOR/NFκB signaling pathway. Biochimica et biophysica acta. Molecular cell research · 19 Jun 2026 PMID 42320860
- Synergistic dual targeting of mTOR and GLS1 overcomes glutamine-driven resistance in triple-negative breast cancer. Pharmacological research · 11 Jun 2026 PMID 42276398
- Multi-mechanistic mitochondria-mediated N-methylated YKWYYRGAA-decorated nano-chitosan conjugate carrier for treatment of NRAS-mutant-harbouring lung carcinoma. Carbohydrate polymers · 2 Jun 2026 PMID 42230031
- Butyrate Regulates the Blood-Brain Barrier Transport and Intraendothelial Accumulation of Alzheimer's Disease Amyloid-Beta Peptides. Molecular pharmaceutics · 21 May 2026 PMID 42166642
- Platelet-rich plasma-primed bone marrow mesenchymal stem cell-derived exosomes inhibit neuronal apoptosis and autophagy, and promote nerve regeneration via the miR-29a-3p/PTEN/PI3K/Akt/mTOR axis after spinal cord injury. Journal of molecular histology · 21 May 2026 PMID 42165939
Unclassified: not yet indexed with MeSH (2)
- A novel mTORC1-NPC2 axis suppresses lipophagy and drives atherosclerotic plaque progression. Biochimica et biophysica acta. Molecular basis of disease · 9 Sept 2026 PMID 42716142
- Urolithin A activates mitophagy via the AMPK-mTOR axis and modulates the gut-ceramide axis to ameliorate cardiac remodeling in HFpEF. Experimental & molecular medicine · 10 Jul 2026 PMID 42432192
Written from 19 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-11 by GPT. Drafted by language models from published abstracts; not medical advice.